An Israeli biotech company has successfully completed trials of a new drug for novel coronavirus, the Israeli Channel 12 News reported Tuesday.
According to the report, the drug, called MesenCure, was developed by Bonus BioGroup company, for the treatment of life-threatening respiratory distress in coronavirus and pneumonia patients.
The report added that the company recently conducted preclinical trials on model animals, showing that the animals’ lungs became healthy after being treated with the drug.
The company now waits for governmental approval to conduct trials on coronavirus patients.
The new drug consists of stem cells taken from a healthy donor’s fat tissue.
These cells, to be transmitted to the patient by blood transfusion, are supposed to reduce inflammation in the lung tissue and help restore the tissue.
In the experiment, the drug was able to reduce 47 percent of the fluid accumulated in the animals’ lungs, the report added. Enditem